Expert Interview
3: Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Ticker(s): KYKOF, AMGNInstitution: Brinton Lake Dermatology
- Board-certified dermatologist who specializes in medical dermatology, including acne, psoriasis, rosacea, eczema and skin cancer
- Performs routine skin cancer checks and has a particular interest in cosmetic dermatology
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
